Inj, carboplatin (avyxa)
Products billed under this code include Kyxata.
Payment limit per 1 MG, by effective quarter, 2Q26 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under J9278
From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Kyxata | Avyxa Pharma, LLC | 83831-0140-02 | 20 | $104.52 |
| Kyxata | Avyxa Pharma, LLC | 83831-0141-08 | 80 | $418.08 |
| Kyxata | Avyxa Pharma, LLC | 83831-0142-50 | 500 | $2,613.00 |
Every quarter
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $5.226 | +$0.023 | 1 MG | Inj, carboplatin (avyxa) | v1, posted September 17, 2026 |
| 3Q26 | $5.203 | −$0.039 | 1 MG | Inj, carboplatin (avyxa) | v1, posted September 15, 2026 |
| 2Q26 | $5.242 | – | 1 MG | Inj, carboplatin (avyxa) | v1, posted September 15, 2026 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.
CMS source files
- 4Q26: 2026-09-17_october-2026-medicare-part-b-payment-limit-files-final.zipposted September 17, 2026
- 4Q26: 2026-09-17_october-2026-ndc-hcpcs-crosswalk-final.zipposted September 17, 2026
- 3Q26: 2026-09-15_july-2026-medicare-part-b-payment-limit-files.zipposted September 15, 2026
- 2Q26: 2026-09-15_april-2026-medicare-part-b-payment-limit-files-final-file.zipposted September 15, 2026